Serum endostatin levels correlate with enhanced extracellular matrix degradation and poor patients' prognosis in bladder cancer

International Journal of Cancer

Volumn 130, Issue 12, 2012, Pages 2922-2929

  Szarvas, Tibor ^a,b   László, Viktória ^a   Vom Dorp, Frank ^a   Reis, Henning ^a   Szendröi, Attila ^c   Romics, Imre ^c   Tilki, Derya ^d   Rübben, Herbert ^a   Ergün, Süleyman ^e  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c SEMMELWEIS UNIVERSITY   (Hungary)

^d LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^e UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

angiogenesis; bladder cancer; endostatin; metastasis; MMP 7; prognosis; serum; urine

Indexed keywords

COLLAGEN TYPE 18; ENDOSTATIN; MATRILYSIN;

ADULT; AGED; ARTICLE; BLADDER CANCER; BLOOD VESSEL; CANCER GRADING; CANCER INVASION; CANCER STAGING; CANCER TISSUE; COLLAGEN TYPE 18 GENE; CONTROLLED STUDY; CYSTECTOMY; DISEASE SPECIFIC SURVIVAL; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX; FEMALE; GENE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; METASTASIS FREE SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN DEPLETION; PROTEIN SYNTHESIS; PROTEIN URINE LEVEL; REAL TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY; TISSUE DISTRIBUTION; TRANSURETHRAL RESECTION; TUMOR VASCULARIZATION;

AGED; AGED, 80 AND OVER; COLLAGEN; DISEASE-FREE SURVIVAL; ENDOSTATINS; EXTRACELLULAR MATRIX; FEMALE; HUMANS; LYMPHATIC METASTASIS; MALE; MATRIX METALLOPROTEINASE 7; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 84859916431     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.26343     Document Type: Article

References (29)

1. Parkin DM, Bray F, Ferlay J, Pisani P,. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108. (Pubitemid 40372904)
2. Kuroi K, Toi M,. Circulating angiogenesis regulators in cancer patients. Int J Biol Markers 2001; 16: 5-26. (Pubitemid 32243577)
3. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J,. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88: 277-85. (Pubitemid 28015876)
4. Lin HC, Chang JH, Jain S, Gabison EE, Kure T, Kato T, Fukai N, Azar DT,. Matrilysin cleavage of corneal collagen type XVIII NC1 domain and generation of a 28-kDa fragment. Invest Ophthalmol Vis Sci 2001; 42: 2517-24. (Pubitemid 32954857)
5. Chang JH, Javier JA, Chang GY, Oliveira HB, Azar DT,. Functional characterization of neostatins, the MMP-derived, enzymatic cleavage products of type XVIII collagen. FEBS Lett 2005; 579: 3601-6. (Pubitemid 40897698)
6. Felbor U, Dreier L, Bryant RA, Ploegh HL, Olsen BR, Mothes W,. Secreted cathepsin L generates endostatin from collagen XVIII. EMBO J 2000; 19: 1187-94. (Pubitemid 30151015)
7. Wen W, Moses MA, Wiederschain D, Arbiser JL, Folkman J,. The generation of endostatin is mediated by elastase. Cancer Res 1999; 59: 6052-56. (Pubitemid 30035619)
8. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS, Cao Y, Sage EH, Folkman J,. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994; 79: 315-28. (Pubitemid 24324921)
9. Fukumoto S, Morifuji M, Katakura Y, Ohishi M, Nakamura S,. Endostatin inhibits lymph node metastasis by a down-regulation of the vascular endothelial growth factor C expression in tumor cells. Clin Exp Metastasis 2005; 22: 31-8. (Pubitemid 41185859)
10. Brideau G, Mäkinen MJ, Elamaa H, Tu H, Nilsson G, Alitalo K, Pihlajaniemi T, Heljasvaara R,. Endostatin overexpression inhibits lymphangiogenesis and lymph node metastasis in mice. Cancer Res 2007; 67: 11528-35.
11. Zhuo W, Luo C, Wang X, Song X, Fu Y, Luo Y,. Endostatin inhibits tumour lymphangiogenesis and lymphatic metastasis via cell surface nucleolin on lymphangiogenic endothelial cells. J Pathol 2010; 222: 249-60.
12. Sund M, Hamano Y, Sugimoto H, Sudhakar A, Soubasakos M, Yerramalla U, Benjamin LE, Lawler J, Kieran M, Shah A, Kalluri R,. Function of endogenous inhibitors of angiogenesis as endothelium-specific tumor suppressors. Proc Natl Acad Sci USA 2005; 102: 2934-9. (Pubitemid 40299894)
13. Woo IS, Kim KA, Jeon HM, Hong SH, Rho SY, Koh SJ, Lee MA, Byun JH, Kang JH, Hong JS, Lee KS, Cho CS, et al. Pretreatment serum endostatin as a prognostic indicator in metastatic gastric carcinoma. Int J Cancer 2006; 119: 2901-6.
14. Feldman AL, Pak H, Yang JC, Alexander HR Jr, Libutti SK,. Serum endostatin levels are elevated in patients with soft tissue sarcoma. Cancer 2001; 91: 1525-9. (Pubitemid 32319264)
15. Feldman AL, Tamarkin L, Paciotti GF, Simpson BW, Linehan WM, Yang JC, Fogler WE, Turner EM, Alexander HR, Libutti SK,. Serum endostatin levels are elevated and correlate with serum vascular endothelial growth factor levels in patients with stage IV clear cell renal cancer. Clin Cancer Res 2000; 6: 4628-34. (Pubitemid 32110397)
16. Suzuki M, Iizasa T, Ko E, Baba M, Saitoh Y, Shibuya K, Sekine Y, Yoshida, Hiroshima K, Fujisawa T,. Serum endostatin correlates with progression and prognosis of non-small cell lung cancer. Lung Cancer 2002; 35: 29-34. (Pubitemid 34028088)
17. Guan KP, Ye HY, Yan Z, Wang Y, Hou SK,. Serum levels of endostatin and matrix metalloproteinase-9 associated with high stage and grade primary transitional cell carcinoma of the bladder. Urology 2003; 61: 719-23. (Pubitemid 36384961)
18. Ii M, Yamamoto H, Adachi Y, Maruyama Y, Shinomura Y,. Role of matrix metalloproteinase-7 (matrilysin) in human cancer invasion, apoptosis, growth, and angiogenesis. Exp Biol Med 2006; 231: 20-7. (Pubitemid 43063974)
19. Szarvas T, Becker M, vom Dorp F, Gethmann C, Tötsch M, Bankfalvi A, Schmid KW, Romics I, Rübben H, Ergün S,. Matrix metalloproteinase-7 as a marker of metastasis and predictor of poor survival in bladder cancer. Cancer Sci 2010; 101: 1300-8.
20. Szarvas T, Singer BB, Becker M, vom Dorp F, Jäger T, SzendrdÌoi A, Riesz P, Romics I, Rübben H, Ergün S,. Urinary matrix metalloproteinase-7 level is associated with the presence of metastasis in bladder cancer. BJU Int 2011; 107: 1069-73.
21. Ergün S, Kilic N, Wurmbach JH, Ebrahimnejad A, Fernando M, Sevinc S, Kilic E, Chalajour F, Fiedler W, Lauke H, Lamszus K, Hammerer P, et al. Endostatin inhibits angiogenesis by stabilization of newly formed endothelial tubes. Angiogenesis 2001; 4: 193-206. (Pubitemid 34174308)
22. Iizasa T, Chang H, Suzuki M, Otsuji M, Yokoi S, Chiyo M, Motohashi S, Yasufuku K, Sekine Y, Iyoda A, Shibuya K, Hiroshima K, et al. Overexpression of collagen XVIII is associated with poor outcome and elevated levels of circulating serum endostatin in non-small cell lung cancer. Clin Cancer Res 2004; 10: 5361-6. (Pubitemid 39100472)
23. vom Dorp F, Börgermann C, Schenck M, Becker M, Rose A, Szarvas T, Rübben H,. Role of lymphadenectomy in patients with invasive urothelial carcinoma of the bladder. Urologe A 2009; 48: 51-3.
24. Stein JP, Lieskovsky G, Cote R, Groshen S, Feng AC, Boyd S, Skinner E, Bochner B, Thangathurai D, Mikhail M, Raghavan D, Skinner DG,. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 2001; 19: 666-75. (Pubitemid 32120143)
25. Bochner BH, Montie JE, Lee CT,. Follow-up strategies and management of recurrence in urologic oncology bladder cancer: invasive bladder cancer. Urol Clin North Am 2003; 30: 777-89. (Pubitemid 37485192)
26. Szarvas T, Jäger T, Tötsch M, vom Dorp F, Kempkensteffen C, Kovalszky I, Romics I, Ergün S, Rübben H,. Angiogenic switch of angiopietins-Tie2 system and its prognostic value in bladder cancer. Clin Cancer Res 2008; 14: 8253-62.
27. Quentin T, Schlott T, Korabiowska M, Käthei N, Zöller G, Glaser F, Kunze E,. Alteration of the vascular endothelial growth factor and angiopoietins-1 and -2 pathways in transitional cell carcinomas of the urinary bladder associated with tumor progression. Anticancer Res 2004; 24: 2745-56. (Pubitemid 39407152)
28. Beecken WD, Engl T, Hofmann J, Jonas D, Blaheta R,. Clinical relevance of serum angiogenic activity in patients with transitional cell carcinoma of the bladder. J Cell Mol Med 2005; 9: 655-61. (Pubitemid 44151952)
29. Charlesworth PJ, Harris AL,. Mechanisms of disease: angiogenesis in urologic malignancies. Nat Clin Pract Urol 2006; 3: 157-69. (Pubitemid 43378858)